EyePoint Pharmaceuticals shares lost nearly 80% of their value following the disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money.

NEW YORK, Oct. 19, 2026 /PRNewswire/ — EyePoint Pharmaceuticals (NASDAQ: EYPT) saw nearly 80% of its market value erased after the market opened following the Company’s disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUCIA trial for wet age-related macular degeneration. If you held EYPT when the LUCIA result reached the market, you may have legal rights. Investors who suffered losses are encouraged to submit your EYPT loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The LUCIA Phase 3 trial’s primary endpoint was statistical non-inferiority in mean change in best corrected visual acuity (BCVA) versus on-label 2 mg aflibercept control. DURAVYU failed to meet this endpoint, despite achieving key secondary endpoints, including a 38% reduction in treatment burden.

EYPT shareholders who lost money on LUCIA are encouraged to request a no-cost review of your EYPT losses or call (212) 363-7500.

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the EYPT Investigation

Q: How much did EYPT stock drop?A: Shares fell roughly 80% after the Company disclosed that its Phase 3 LUCIA trial of DURAVYU did not meet its primary endpoint of non-inferiority to on-label aflibercept. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: When did EyePoint Pharmaceuticals allegedly mislead investors?A: The investigation concerns statements made before the LUCIA disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: Who is eligible to participate in the EYPT investigation?A: Investors who purchased EYPT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What do EYPT investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my EYPT shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EYPT and sold at a loss may still participate in the investigation.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/eyepoint-pharmaceuticals-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-eyepoint-pharmaceuticals-eypt-302913078.html

SOURCE Levi & Korsinsky, LLP